Donggeon Kim’s Post

Eisai Co., Ltd.'s DAC Research 1. Delivering EBET using the CEACAM6 antibody degrades BRD (bromodomain proteins) in CEACAM6-positive pancreatic cancer cells. 2. They regulate pancreatic cancer stromal signaling through a bystander effect on CEACAM6-negative CAFs (cancer-associated fibroblasts). STAT3, a key signaling molecule in CAFs, is functionally linked to BRD2/4, and EBET payloads diffused from pancreatic cancer cells inhibit STAT3 signaling in CAFs. 3. The #84.7 antibody has a lower binding affinity to normal cells like MPCs (myeloid progenitor cells) than existing CEACAM6 antibodies, reducing side effects on normal cells.

Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses https://lnkd.in/gpfYYvx4  

Sharma A et al published an article: "LncRNA HULC augments high glucose-associated pancreatic cancer progression and drug resistance by enhancing YAP activity and autophagy" Inhibition of lncRNA highly upregulated in liver cancer (HULC) and YAP may represent a novel therapeutic strategy for pancreatic ductal adenocarcinoma cells (PDAC). Furthermore, this study portrays the intricate molecular interplay between HULC, YAP and autophagy in PDAC pathogenesis. https://lnkd.in/gT-BcFdm

An excellent 𝑵𝒂𝒕𝒖𝒓𝒆 𝑪𝒐𝒎𝒎𝒖𝒏𝒊𝒄𝒂𝒕𝒊𝒐𝒏𝒔 paper by Youya Nakazawa et al. describing yet another innovative ADC structure. In the paper the authors show preclinical efficacy in a pancreatic cancer model of an ADC composed of a BET protein-degrader 'warhead' conjugated to an anti-CEACAM6 antibody. https://lnkd.in/eUK_P294

Excited to share the publication of our systematic review “Targeting BCL-2 Family Proteins Using BH3 Mimetic Drugs for Cancer Therapy: A Systematic Review of Randomized Clinical Trials.” This study rigorously analyzes clinical trial data to assess the safety and effectiveness BH3 mimetic drugs in malignancies. A big thank you to Mohammad Ashrafuzzaman and Fatimah Alharbi for their support and contribution. Evidence-based research is essential in advancing medicine and patient outcomes. https://lnkd.in/dAzyxb_9 #Science #Medicine #Cancer #Oncology #ClinicalTrials

🧬 #CDH6 The CDH6-targeting antibody-drug conjugate (#ADC), Raludotatug Deruxtecan, shows promising results for ovarian cancer treatment. In a Phase I trial, it achieved a 46% objective response rate and a 98% disease control rate. This breakthrough highlights #CDH6 as a key target for innovative therapies. Learn more about this development at DIMA Biotech's blog: https://lnkd.in/eEpn7McT #CancerResearch #OvarianCancer #Biotech #ADC #CDH6

Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses https://lnkd.in/gpfYYvx4  

Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses https://lnkd.in/gpfYYvx4  

Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses https://lnkd.in/gpfYYvx4  

USP21 controls STAT3 activity and mitochondrial function of cancer cells justifying development of USP21 inhibitors. #mitochondria #drugdevelopment #deubiquitinase #cancer #STAT3 #cancermetabolism #cancertherapy #bioenergy #ATPproduction